- Home
- FMST vs SNTI Comparison
FMST vs SNTI Comparison
Compare FMST & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FMST | SNTI |
|---|---|---|
| Founded | 2005 | 2016 |
| Country | Canada | United States |
| Employees | 2 | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.5M | 24.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | FMST | SNTI |
|---|---|---|
| Price | $1.99 | $0.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | ★ 135.4K | 109.2K |
| Earning Date | 02-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $150.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.60 | $0.80 |
| 52 Week High | $5.74 | $5.10 |
Technical Indicators
Market Signals| Indicator | FMST | SNTI |
|---|---|---|
| Relative Strength Index (RSI) | 42.49 | 42.51 |
| Support Level | $1.73 | $0.80 |
| Resistance Level | $2.52 | $1.02 |
| Average True Range (ATR) | 0.17 | 0.05 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 8.77 | 28.72 |
Price Performance
Historical ComparisonAbout FMST Foremost Lithium Resource & Technology Ltd.
Foremost Clean Energy Ltd is an emerging North American uranium and lithium exploration company. Its uranium portfolio consists of projects at different stages of exploration from grassroots, to those with historical exploration and drill-ready targets. It also maintains a secondary portfolio of lithium projects at different stages of development spanning 50,000-plus acres across Manitoba and Quebec. Geographically it covers Canada and United states.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.